CD44 and cancer: An interesting observation during this study was the altered surface expression of the cancer stem cell markers, CD44, CD133 and EpCAM between parent and cisplatin resistant NSCLC cell lines, in addition to stemness markers in ALDH1 cell fractions derived from cisplatin resistant sublines.